Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 65 of 95, showing 5 Applications out of 474 total, starting on record 321, ending on 325

# Protocol No Study Title Investigator(s) & Site(s)

321.

ECCT/21/11/08   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Videlis N Nduba
2. Prof. Jessie N Githanga
3. Fredrick Sirwa Chite
4. Bernhards Ragama Ogutu
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
3. Gertrude’s Children’s Hospital. (Nairobi City county)
4. Strathmore University Medical Centre (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
View

322.

ECCT/21/11/04   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Prof Jessie N Githanga
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
View

323.

ECCT/19/05/01   A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults
    A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
KAVI-ICR KNH SITE
 
View

324.

ECCT/15/05/01   Janssen Ebola vaccine study
    A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa   
Principal Investigator(s)
1. Prof Omu Aggrey Anzala
Site(s) in Kenya
KAVI –Institute of Clinical Research
 
View

325.

ECCT/16/11/04   RV456
    A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo   
Principal Investigator(s)
1. JANET OYIEKO
Site(s) in Kenya
KOMBEWA CLINICAL RESEARCH CENTRE
 
View